IRIS
PALUMBO, Giuseppe Alberto Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.974
EU - Europa 3.948
AS - Asia 3.922
SA - Sud America 706
AF - Africa 397
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 17.969
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.693
SG - Singapore 1.905
IT - Italia 1.442
CN - Cina 1.402
IE - Irlanda 960
BR - Brasile 637
UA - Ucraina 557
CI - Costa d'Avorio 249
CA - Canada 235
KR - Corea 222
RU - Federazione Russa 213
DE - Germania 160
SE - Svezia 135
IN - India 88
GB - Regno Unito 83
VN - Vietnam 81
FI - Finlandia 80
SN - Senegal 75
FR - Francia 51
BE - Belgio 49
CH - Svizzera 39
NL - Olanda 39
MX - Messico 32
JP - Giappone 31
CZ - Repubblica Ceca 30
BD - Bangladesh 26
AR - Argentina 24
ES - Italia 22
PL - Polonia 22
HK - Hong Kong 21
UZ - Uzbekistan 21
AT - Austria 20
NG - Nigeria 20
TR - Turchia 20
ZA - Sudafrica 18
IQ - Iraq 16
GR - Grecia 15
PK - Pakistan 15
LB - Libano 13
AU - Australia 12
MA - Marocco 12
CO - Colombia 11
KE - Kenya 11
VE - Venezuela 10
JO - Giordania 9
IL - Israele 8
IR - Iran 8
EC - Ecuador 7
EU - Europa 7
LT - Lituania 7
EG - Egitto 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
RO - Romania 5
SA - Arabia Saudita 5
CL - Cile 4
PY - Paraguay 4
AM - Armenia 3
AZ - Azerbaigian 3
BO - Bolivia 3
HN - Honduras 3
NO - Norvegia 3
NP - Nepal 3
OM - Oman 3
PE - Perù 3
PS - Palestinian Territory 3
AL - Albania 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
PT - Portogallo 2
UY - Uruguay 2
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
LU - Lussemburgo 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PG - Papua Nuova Guinea 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
ZW - Zimbabwe 1
Totale 17.969
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.457
Singapore 1.191
Dublin 935
Chandler 923
Houston 780
Dallas 622
Jacksonville 536
Chicago 532
Hefei 423
Boardman 386
Catania 332
Ashburn 329
Abidjan 249
Lawrence 248
Cambridge 245
Andover 241
Seoul 222
Nanjing 212
Beijing 161
Toronto 152
Civitanova Marche 132
Des Moines 129
Los Angeles 117
Wilmington 107
San Mateo 90
Rome 86
Dakar 75
Milan 75
Nanchang 72
The Dalles 63
Florence 57
Saint Petersburg 57
Shenyang 57
São Paulo 56
Hebei 54
Jiaxing 52
Columbus 51
Ottawa 49
Council Bluffs 48
Brussels 46
Grafing 46
Munich 45
Palermo 44
Changsha 41
Dong Ket 40
Washington 39
Tianjin 34
Falls Church 29
Helsinki 29
Seattle 29
Lappeenranta 28
Messina 27
New York 27
Brooklyn 25
Tokyo 23
Turku 23
Boston 22
Hanoi 22
San Francisco 22
Kochi 21
Abuja 20
Hong Kong 20
Moscow 20
Rio de Janeiro 19
Bronte 18
Den Haag 18
Naples 18
Brno 16
Bari 15
Bremen 15
Amsterdam 14
Belo Horizonte 14
Chennai 14
Jinan 14
Stockholm 14
Turin 14
Warsaw 14
Ann Arbor 13
Mexico City 13
Montreal 13
Pune 12
Atlanta 11
Augusta 11
Curitiba 11
Guangzhou 11
Misterbianco 11
Mumbai 11
Paris 11
Goiânia 10
Kunming 10
London 10
Nairobi 10
Norwalk 10
Aci Sant'Antonio 9
Campinas 9
Ho Chi Minh City 9
Johannesburg 9
Amman 8
Brasília 8
Dhaka 8
Totale 12.780
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 236
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes 215
Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population 196
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 170
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 152
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 139
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 135
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 131
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 122
IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia 116
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 109
Hedgehog signaling pathways in multiple myeloma 105
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 105
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 104
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 102
A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells 102
Focus on Osteosclerotic Progression in Primary Myelofibrosis 102
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 101
A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus Gland function 99
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside 99
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 99
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 98
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 96
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 95
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 95
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 94
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 94
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 94
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 93
Terapia del mieloma multiplo 93
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 93
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 93
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 92
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 91
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 90
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 88
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 88
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 87
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 87
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 86
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 86
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 85
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 84
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 84
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 83
Angiogenesis in acute myeloid leukemia 83
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 83
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 82
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation 81
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 80
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 80
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 78
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 77
A case of high-risk AML in a patient with advanced systemic mastocytosis 77
Effects of imatinib mesylate in osteoblastogenesis 77
Emangioma, plasmocitoma e mieloma multiplo del rachide 77
ITF2357 Interferes with apoptosis and inflammatory pathways in the HL-60 model: A gene expression study 77
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 75
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 75
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 75
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 75
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 74
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 74
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 74
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 74
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 74
Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models 73
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 73
Correction to: Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models (Antioxidants, (2022), 11, 8, (1596), 10.3390/antiox11081596) 73
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS 73
Hypoxia Induces Imatinib Resistance in CML Cell Lines 73
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 73
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 72
Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients 72
IMATINIB INCREASES CYTOTOXICITY OF MELPHALAN AND DECREASES PROLONGATION OF G2-M PHASE IN HUMAN K562 CELLS 72
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations 72
Evaluation of taxol cytotoxicity on B-CLL cells in vitro 71
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 71
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: An ex-vivo study 71
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality 71
In vitro sensitivity of B-CLL cells to Fludarabine and Interferons 70
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 70
Multidrug resistance mechanisms in chronic lymphocytic leukaemia 69
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 69
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: A single-centre cohort pilot study 69
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients 68
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 68
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview 68
Cross-talk communication in the neuroendocrine-reproductive-immune axis. Age-dependent alterations in the common communication networks. 67
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 67
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 67
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 67
Il mitoxantrone in polichemioterapia associato allo schema CVP nel trat- tamento dei linfomi non hodgkin. 67
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 66
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib 66
IMPACT OF EPOETIN ZETA (BIOSIMILAR EPO alpha) IN LOW-RISK MDS: ITT ANALYSIS OF A MULTICENTRIC PHASE 2 STUDY 66
Peptidergic modulation of immune system development: role of luteinizing hormone-releasing hormone. 66
Multiple Myeloma in 2023 Ways: From Trials to Real Life 65
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 65
Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells 65
Totale 8.885
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.066
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.066
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.010 0 0 107 49 367 16 118 13 131 12 117 80
2021/20221.799 150 246 2 13 363 38 271 77 158 32 35 414
2022/20233.042 278 147 73 212 249 522 28 515 738 56 154 70
2023/20241.805 111 246 93 127 87 339 97 133 10 51 320 191
2024/20256.208 56 954 344 315 1.336 633 219 234 442 614 527 534
2025/20262.240 863 1.302 75 0 0 0 0 0 0 0 0 0
Totale 18.481